Anti-CD59/ 16.3A5/ 1F5 monoclonal antibody
Anti-CD59/ 16.3A5/ 1F5 antibody for FACS & in-vivo assay
Go to CD59/CD59 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T78552-Ab-1/ GM-Tg-hg-T78552-Ab-2 | Anti-Human CD59 monoclonal antibody | Human |
GM-Tg-rg-T78552-Ab-1/ GM-Tg-rg-T78552-Ab-2 | Anti-Rat CD59 monoclonal antibody | Rat |
GM-Tg-mg-T78552-Ab-1/ GM-Tg-mg-T78552-Ab-2 | Anti-Mouse CD59 monoclonal antibody | Mouse |
GM-Tg-cynog-T78552-Ab-1/ GM-Tg-cynog-T78552-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CD59 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T78552-Ab-1/ GM-Tg-felg-T78552-Ab-2 | Anti-Feline CD59 monoclonal antibody | Feline |
GM-Tg-cang-T78552-Ab-1/ GM-Tg-cang-T78552-Ab-2 | Anti-Canine CD59 monoclonal antibody | Canine |
GM-Tg-bovg-T78552-Ab-1/ GM-Tg-bovg-T78552-Ab-2 | Anti-Bovine CD59 monoclonal antibody | Bovine |
GM-Tg-equg-T78552-Ab-1/ GM-Tg-equg-T78552-Ab-2 | Anti-Equine CD59 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T78552-Ab-1/ GM-Tg-hg-T78552-Ab-2; GM-Tg-rg-T78552-Ab-1/ GM-Tg-rg-T78552-Ab-2; GM-Tg-mg-T78552-Ab-1/ GM-Tg-mg-T78552-Ab-2; GM-Tg-cynog-T78552-Ab-1/ GM-Tg-cynog-T78552-Ab-2; GM-Tg-felg-T78552-Ab-1/ GM-Tg-felg-T78552-Ab-2; GM-Tg-cang-T78552-Ab-1/ GM-Tg-cang-T78552-Ab-2; GM-Tg-bovg-T78552-Ab-1/ GM-Tg-bovg-T78552-Ab-2; GM-Tg-equg-T78552-Ab-1/ GM-Tg-equg-T78552-Ab-2 |
Products Name | Anti-CD59 monoclonal antibody |
Format | mab |
Target Name | CD59 |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-CD59 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species CD59/ 16.3A5/ 1F5 VLP (virus-like particle) (Products Developing) |
ORF Viral Vector | pGMAAV000004 | human CD59 AAV plasmid |
ORF Viral Vector | vGMAAV000004 | human CD59 AAV particle |
Target information
Target ID | GM-T78552 |
Target Name | CD59 |
Gene ID | 966,25407,693402,475945,101092210,505574,106781397 |
Gene Symbol and Synonyms | 16.3A5,1F5,CD59,Cd59a,Cd59b,EJ16,EJ30,EL32,G344,HRF-20,HRF20,MAC-IP,MACIF,MACIP,MEM43,MIC11,MIN1,MIN2,MIN3,MIRL,MSK21,p18-20 |
Uniprot Accession | P13987,P27274 |
Uniprot Entry Name | CD59_HUMAN,CD59_RAT |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target |
Disease | Ovary Cancer, Contact with and (suspected) exposure to environmental tobacco smoke (acute) (chronic), Contrast - Induced Nephropathy, Dent disease, IgA glomerulonephritis, Ovarian cancer, Type 1 diabetes mellitus |
Gene Ensembl | ENSG00000085063 |
Target Classification | N/A |
The target: CD59, gene name: CD59, also named as 16.3A5, 1F5, EJ16, EJ30, EL32, G344, HRF-20, HRF20, MAC-IP, MACIF, MEM43, MIC11, MIN1, MIN2, MIN3, MIRL, MSK21, p18-20. This gene encodes a cell surface glycoprotein that regulates complement-mediated cell lysis, and it is involved in lymphocyte signal transduction. This protein is a potent inhibitor of the complement membrane attack complex, whereby it binds complement C8 and/or C9 during the assembly of this complex, thereby inhibiting the incorporation of multiple copies of C9 into the complex, which is necessary for osmolytic pore formation. This protein also plays a role in signal transduction pathways in the activation of T cells. Mutations in this gene cause CD59 deficiency, a disease resulting in hemolytic anemia and thrombosis, and which causes cerebral infarction. Multiple alternatively spliced transcript variants, which encode the same protein, have been identified for this gene. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.